New research analyzing fitness tracker data reveals a paradoxical trend among patients taking popular GLP-1 weight loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound. While these medications successfully reduce body weight, users simultaneously experience significant declines in daily physical activity levels. Researchers examined comprehensive Fitbit data from GLP-1 users before and after treatment initiation, identifying a consistent pattern of decreased step counts and reduced exercise frequency despite successful weight loss outcomes. This unexpected finding challenges conventional assumptions that weight loss improvements would naturally encourage increased physical activity. The observation raises important clinical questions about the long-term health implications of reduced movement during pharmacological weight loss treatment, particularly regarding muscle mass preservation and overall metabolic health. Medical professionals may need to counsel patients on maintaining regular physical activity alongside medication use. Read the full article on GMJ Newsroom.
Was this article helpful?
